Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422344 · ClinicalTrials.gov registry record · Phase 1
A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00422344: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00422344 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00422344, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of RAD-001 and Sunitinib given in combination for renal cell cancer. We also want to find out what effects (good and bad) the combination of RAD-001 and Sunitinib have on you and your tumor. RAD001 is a pill that works by shutting down some of the pathways in the cell that make tumors grow. Sunitinib is a pill that works by shutting off the signal in the cancer cells that tell the cells to grow blood vessels. Without this signal, the blood vessels to the tumors shrink down.
Interventions
- DRUG RAD001, Sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422344
The ClinicalTrials.gov registry entry for NCT00422344 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAD001, Sunitinib is the first listed.
NCT00422344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00422344 about?
NCT00422344 is a clinical study titled "A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma". The purpose of this study is to test the safety of RAD-001 and Sunitinib given in combination for renal cell cancer. We also want to find out what effects (good and bad) the combination of RAD-001 and Sunitinib have on you and your tumor. RAD001 is a pill that works by shutting down some of the pat...
What is the current status of trial NCT00422344?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2006-10. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00422344?
The interventions under investigation include: RAD001, Sunitinib (DRUG).
Who is sponsoring clinical trial NCT00422344?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.